The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: A Phase III Clinical Trial of a 11-valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) in Chinese Women Aged 9-45 Years
Official Title: A Multicenter Randomized, Blinded, Placebo-controlled Phase III Clinical Trial Evaluating the Protective Efficacy, Safety and Immunogenicity of a 11-valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) in Chinese Women Aged 9-45 Years
Study ID: NCT05262010
Brief Summary: A total of 13500 Chinese women aged 18-45 years old were divided into three age groups: 18-26 years old, 27-35 years old, and 35-45 years old. The experimental group and the placebo group were randomly assigned in a ratio of 1:1. All subjects enrolled in the upper arm deltoid muscle were injected with 3 doses of test vaccine or placebo according to the 0, 2, and 6 months immunization program.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT
Sex: FEMALE
Healthy Volunteers: Yes
Hechi Yizhou District Center for Disease Control and Prevention, Hechi, Guangxi, China
Hezhou Center for Disease Control and Prevention, Hezhou, Guangxi, China
Lianyuan Center for Disease Control and Prevention, Lianyuan, Hunan, China
Qiyang Center for Disease Control and Prevention, Qiyang, Hunan, China
Yongji Center for Disease Control and Prevention, Yongji, Shanxi, China
Yuanqu Center for Disease Control and Prevention, Yuncheng, Shanxi, China
Mianyang Youxian District Center for Disease Control and Prevention, Mianyang, Sichuan, China
Neijiang Shizhong District Center for Disease Control and Prevention, Neijiang, Sichuan, China